ECS Botanics Achieves Positive EBITDA with Strong Branded Sales and Global Expansion

Financial Turnaround Amid Statutory Loss

ECS Botanics Holdings Ltd (ASX:ECS) reported a marked operational turnaround in FY26, posting a positive EBITDA of $0.6 million, a $5.8 million improvement from the prior year’s $5.2 million loss. Revenue grew 10% to $21.4 million, driven by a surge in branded product sales, yet the company still recorded a statutory net loss after tax of $1.9 million. This loss was primarily due to non-cash impairment charges totalling around $3.35 million related to inventory and receivables, which do not affect cash flow.

Operating cash flow swung from a $5.1 million outflow in FY25 to a positive $0.5 million in FY26, reflecting improved cash generation and operational discipline. The loss before tax narrowed sharply to $1.0 million from $6.9 million the previous year, underscoring the progress ECS has made in stabilising its financial footing.

Branded Portfolio Fuels Growth

The standout feature of ECS’s FY26 performance was the rapid expansion of its branded B2C revenue, which doubled to $13.7 million and now accounts for approximately 65% of total sales. This growth offset softness in lower-margin wholesale channels and highlights ECS’s strategic pivot towards capturing more value through differentiated, finished-dose products.

OzSun, ECS’s flagship brand, emerged as the largest revenue contributor, capturing nearly 40% of sales and strengthening its foothold in the value segment of the Australian medicinal cannabis market. The company also broadened its portfolio with the launch of AVANI AVA, targeting women’s health, and Gelonoidz #20, the first Australian-grown Terphogz product, enhancing its premium offerings.

Independent prescription data from NostraData showed ECS branded volumes grew 18.1% over the six months to June 2026, outperforming the broader market’s 15.8% decline, a sign of effective brand engagement and product acceptance.

Operational Efficiencies and Production Gains

FY26 was the first full year benefiting from ECS’s prior investments in cultivation infrastructure. Outdoor trimmed flower yield rose 12% to 3.1 tonnes, while production from 26 Protective Cropping Enclosures (PCEs) jumped 43% to 5.3 tonnes of untrimmed dried flower. These gains stemmed from improved genetics, cultivation techniques, and harvesting methods.

Crucially, ECS cut average production costs per gram by 33% across the PCE network and 44% for outdoor cultivation compared to FY25, reflecting better asset utilisation and process optimisation. With major infrastructure investments now largely complete, the company’s focus has shifted to maximising returns from its existing asset base rather than capacity expansion.

International Expansion Gains Traction

ECS made significant strides in international markets, an area it has identified as a key growth driver. The commercial launch of OzSun in Germany through a partnership with Nimbus Health saw initial shipments sell out within weeks, validating ECS’s strategy to replicate its Australian branded model in Europe.

In New Zealand, ECS dispatched its first commercial shipment of 1,000 units of 10THC:10CBD medicinal cannabis oil to NUBU Pharmaceuticals, which placed a repeat order post-launch. Meanwhile, regulatory approval of ECS’s first medicinal cannabis product in Poland signals imminent commercial flower supply expected by the end of 2026.

These international developments leverage ECS’s Australian-grown provenance, certified-organic cultivation, and integrated GMP manufacturing platform, providing a competitive edge in regulated markets.

Capital Management and Corporate Governance

At 30 June 2026, ECS held $1.69 million in cash and had $2.81 million in undrawn debt facilities with NAB, supporting ongoing operations and growth initiatives. The company reported no dividends and continues to prioritise disciplined capital management.

The board saw the resignation of non-executive director Rachel Swift during the year. ECS maintains a lean governance structure appropriate to its scale and remains committed to transparency and compliance, as reflected in its comprehensive annual report and auditor’s endorsement.

Looking Ahead: Execution and Selective Growth

With its major infrastructure investments behind it, ECS enters FY27 focused on extracting greater value from its platform. Priorities include scaling branded B2C sales domestically, expanding OzSun’s presence in Germany, increasing export revenue, and further developing its AVANI AVA and Terphogz portfolios.

The company’s upcoming launch of two 2g OzSun rosin blend inhalation products in Australia under a capital-efficient consignment model exemplifies its strategy to grow higher-margin finished-dose formats without heavy capital outlay. This measured approach aims to convert recent operational gains into sustainable earnings and cash flow growth.